Biomarkers for assessing liver function
    1.
    发明授权
    Biomarkers for assessing liver function 有权
    用于评估肝功能的生物标志物

    公开(公告)号:US08455220B2

    公开(公告)日:2013-06-04

    申请号:US12440170

    申请日:2007-09-07

    IPC分类号: C12P21/04

    摘要: A method for assessing liver function in an individual, which method comprises determining the level of methylarginine(s) (such as ADMA and/or SDMA) and the ratio of ischemia modified albumin (IMA): albumin ratio (IMAR) in the individual, thereby to assess liver function in the individual.

    摘要翻译: 一种用于评估个体肝功能的方法,该方法包括测定个体中甲基精氨酸(例如ADMA和/或SDMA)的水平和缺血修饰白蛋白(IMA):白蛋白比例(IMAR)的比例, 从而评估个体的肝功能。

    Prognosis and therapy of liver failure
    2.
    发明申请
    Prognosis and therapy of liver failure 有权
    肝功能衰竭的预后与治疗

    公开(公告)号:US20100297018A1

    公开(公告)日:2010-11-25

    申请号:US12311605

    申请日:2007-10-29

    摘要: A method for assessing prognosis in an individual suffering from liver failure, which method comprises detecting endotoxin in the individual, for example by determining the neutrophil function in the individual. The method can be used to determine whether there is an increased risk of infection in the individual, an increased risk of organ failure in the individual, an increased risk of mortality in the individual and/or an increased risk that the individual will not respond positively to treatment with an immunosuppressive agent, a steroid or an antibiotic.

    摘要翻译: 一种用于评估患有肝衰竭的个体的预后的方法,该方法包括检测个体中的内毒素,例如通过测定个体中的嗜中性粒细胞功能。 该方法可以用于确定个体感染风险是否增加,个体器官衰竭的风险增加,个体死亡风险增加和/或个体不会积极响应的风险增加 用免疫抑制剂,类固醇或抗生素治疗。

    Prognosis and therapy of liver failure
    3.
    发明授权
    Prognosis and therapy of liver failure 有权
    肝功能衰竭的预后与治疗

    公开(公告)号:US08415117B2

    公开(公告)日:2013-04-09

    申请号:US12311605

    申请日:2007-10-29

    IPC分类号: C12Q1/02 A61K35/14

    摘要: A method for assessing prognosis in an individual suffering from liver failure, which method comprises detecting endotoxin in the individual, for example by determining the neutrophil function in the individual. The method can be used to determine whether there is an increased risk of infection in the individual, an increased risk of organ failure in the individual, an increased risk of mortality in the individual and/or an increased risk that the individual will not respond positively to treatment with an immunosuppressive agent, a steroid or an antibiotic.

    摘要翻译: 一种用于评估患有肝衰竭的个体的预后的方法,该方法包括检测个体中的内毒素,例如通过测定个体中的嗜中性粒细胞功能。 该方法可以用于确定个体感染风险是否增加,个体器官衰竭的风险增加,个体死亡风险增加和/或个体不会积极响应的风险增加 用免疫抑制剂,类固醇或抗生素治疗。

    Therapy for liver disease
    5.
    发明申请
    Therapy for liver disease 有权
    肝病治疗

    公开(公告)号:US20100025328A1

    公开(公告)日:2010-02-04

    申请号:US12312028

    申请日:2007-10-29

    CPC分类号: A61M1/3496

    摘要: The invention provides an apparatus for use in the treatment of an individual suffering from liver disease, including: (a) means for selectively removing albumin from the blood of the individual; and (b) means for selectively removing endotoxin from the blood of the individual.

    摘要翻译: 本发明提供了一种用于治疗患有肝脏疾病的个体的装置,包括:(a)用于从个体的血液中选择性除去白蛋白的装置; 和(b)用于从个体的血液中选择性地除去内毒素的装置。

    Therapy for liver disease
    6.
    发明授权
    Therapy for liver disease 有权
    肝病治疗

    公开(公告)号:US08480607B2

    公开(公告)日:2013-07-09

    申请号:US12312028

    申请日:2007-10-29

    IPC分类号: A61M1/16 A61M1/34

    CPC分类号: A61M1/3496

    摘要: The invention provides an apparatus for use in the treatment of an individual suffering from liver disease, including: (a) means for selectively removing albumin from the blood of the individual; and (b) means for selectively removing endotoxin from the blood of the individual.

    摘要翻译: 本发明提供了一种用于治疗患有肝脏疾病的个体的装置,包括:(a)用于从个体的血液中选择性除去白蛋白的装置; 和(b)用于从个体的血液中选择性地除去内毒素的装置。